You are here: Industry Insights > Sanofi

News List

Sanofi makes ex-Roche scientist new R&D chief pharmafile
April 26, 2018
With the retirement of Elias Zerhouni as Head of Global R&D, Sanofi had to find a suitable replacement and believes it has found the man in John Reed (pictured above).
New Sanofi R&D Boss Marks Yet Another High-Profile Industry Executive Change biospace
April 25, 2018
Paris-based Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
Sanofi Pasteur’s vaccine facility to be set up in Toronto expressbpd
April 19, 2018
Governments of Canada and Ontario have announced an investment of up to $70 million towards Sanofi Pasteur’s $500-million project
Sanofi ups the ante in vaccines with new €350M plant fiercepharma
April 18, 2018
Sanofi CEO Olivier Brandicourt took a hard look at the French drugmaker's operations after he took the helm—and he put its vaccines business front and center in the company's growth plans.
Sanofi to Sell its Generic Division to Advent for $2.4 Billion biospace
April 18, 2018
Paris-based Sanofi has agreed to sell its generics division, Zentiva, to Advent International.
Sanofi looks to trim down with divestments pharmafile
April 17, 2018
Sanofi has begun part of a larger process of slimming down its business with the sales of 12 medicines.
Sanofi to invest in Canadian vaccine facility biospectrumasia
April 16, 2018
The investment bolsters the company's Canadian operations and its commitment to advancing public health around the world.
Sanofi to invest €350m in new Canadian vaccine plant pharmafile
April 13, 2018
Sanofi has announced plans to spend €350 million on a new vaccine facility located in Toronto, Canada, a move which, according to the company, is one of its biggest-ever investments in a single building.
EMA to review Sanofi’s Dupixent drug for asthma pharmaceutical-technolog
April 09, 2018
The European Medicines Agency (EMA) has agreed to review an application submitted by Sanofi for the use of Dupixent (dupilumab) to treat inadequately controlled moderate-to-severe asthma.
EMA agrees to review Sanofi's filing for dual SGLT-1/2 inhibitor sotagliflozin in type 1 diabetes firstwordpharma
March 30, 2018
Sanofi announced Thursday that the European Medicines Agency (EMA) has accepted to review its marketing application for the experimental oral drug sotagliflozin

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page